Radiosensitivity of prostate cancer cells is enhanced by EGFR inhibitor C225. (Q53453341)

14 May 2018

title

Radiosensitivity of prostate cancer cells is enhanced by EGFR inhibitor C225. (English)

1 reference

14 May 2018

author name string

Feng Liu

1

1 reference

14 May 2018

Jun-Jie Wang

2

1 reference

14 May 2018

Zhen-Yu You

3

1 reference

14 May 2018

Ying-Dong Zhang

4

1 reference

14 May 2018

Yong Zhao

5

1 reference

14 May 2018

publication date

16 September 2008

1 reference

14 May 2018

published in

Urologic Oncology

1 reference

14 May 2018

volume

28

1 reference

14 May 2018

issue

1

1 reference

14 May 2018

page(s)

59-66

1 reference

14 May 2018

Gefitinib-trastuzumab combination on hormone-refractory prostate cancer xenograft

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2008.07.001

Inhibition of EGFR signaling in human prostate cancer PC-3 cells by combination treatment with beta-phenylethyl isothiocyanate and curcumin.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2008.07.001

Combined targeting of epidermal growth factor receptor and hedgehog signaling by gefitinib and cyclopamine cooperatively improves the cytotoxic effects of docetaxel on metastatic prostate cancer cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2008.07.001

Racial Disparity of Epidermal Growth Factor Receptor Expression in Prostate Cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2008.07.001

A novel acylglycerol kinase that produces lysophosphatidic acid modulates cross talk with EGFR in prostate cancer cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2008.07.001

Blockage of epidermal growth factor receptor by quinazoline tyrosine kinase inhibitors suppresses growth of human hepatocellular carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2008.07.001

Radiation-induced epidermal growth factor receptor nuclear import is linked to activation of DNA-dependent protein kinase

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2008.07.001

Sparing of the penile bulb and proximal penile structures with intensity-modulated radiation therapy for prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2008.07.001

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2008.07.001

Systematic review: comparative effectiveness and harms of treatments for clinically localized prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2008.07.001

Construction of anti-EGFR immunoliposomes via folate-folate binding protein affinity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2008.07.001

Comparison of the epidermal growth factor receptor gene and protein in primary non-small-cell-lung cancer and metastatic sites: implications for treatment with EGFR-inhibitors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2008.07.001

Head and neck cancer as a clinical model for molecular targeting of therapy: combining EGFR blockade with radiation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2008.07.001

Mutant epidermal growth factor receptor (EGFRvIII) contributes to head and neck cancer growth and resistance to EGFR targeting

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2008.07.001

Supra-additive antitumor effect of sunitinib malate (SU11248, Sutent) combined with docetaxel. A new therapeutic perspective in hormone refractory prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2008.07.001

Nutlin-3 radiosensitizes hypoxic prostate cancer cells independent of p53.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2008.07.001

p21-dependent inhibition of colon cancer cell growth by mevastatin is independent of inhibition of G1 cyclin-dependent kinases

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2008.07.001

Acacetin inhibits cell growth and cell cycle progression, and induces apoptosis in human prostate cancer cells: structure-activity relationship with linarin and linarin acetate

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2008.07.001

Silencing of survivin gene by small interfering RNAs produces supra-additive growth suppression in combination with 17-allylamino-17-demethoxygeldanamycin in human prostate cancer cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2008.07.001

Fibronectin Protects Prostate Cancer Cells from Tumor Necrosis Factor-α-induced Apoptosis via the AKT/Survivin Pathway

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2008.07.001

The p38 MAPK pathway mediates aryl propionic acid induced messenger rna stability of p75 NTR in prostate cancer cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2008.07.001

c-myc Promoter-binding protein 1 (MBP-1) regulates prostate cancer cell growth by inhibiting MAPK pathway

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2008.07.001

Ghrelin and a novel preproghrelin isoform are highly expressed in prostate cancer and ghrelin activates mitogen-activated protein kinase in prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2008.07.001

The power and promise of "rewiring" the mitogen-activated protein kinase network in prostate cancer therapeutics

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2008.07.001

Evasion of early cellular response mechanisms following low level radiation-induced DNA damage.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2008.07.001

Relative biologic effectiveness in terms of tumor response of 125I implants compared with 60Co gamma rays

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2008.07.001

The determination of radiobiologically optimized half-lives for radionuclides used in permanent brachytherapy implants

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2008.07.001

Cell cycle perturbations and radiosensitization effects in a human prostate cancer cell line

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2008.07.001

Role of cell cycle in mediating sensitivity to radiotherapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2008.07.001

End-stage differentiation of neutrophil granulocytes in vivo is accompanied by up-regulation of p27kip1 and down-regulation of CDK2, CDK4, and CDK6

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2008.07.001

Selenium inhibition of survivin expression by preventing Sp1 binding to its promoter

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2008.07.001

Bax activation and translocation to mitochondria mediate EGF-induced programmed cell death

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2008.07.001

EGFR enhances Survivin expression through the phosphoinositide 3 (PI-3) kinase signaling pathway

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2008.07.001

10.1016/J.UROLONC.2008.07.001

7 January 2021

Identifiers

DOI

1 reference

14 May 2018

PubMed ID

18799330

1 reference

14 May 2018